Avantor, Inc. reports developments as a life science tools company supplying mission-critical products and services to life sciences and advanced technology customers through its VWR Distribution & Services and Bioscience & Medtech Products businesses. Recurring updates cover earnings, cash flow, leverage, guidance, segment performance and the company’s Revival transformation program, including VWR brand activity, manufacturing and supply-chain improvements and e-commerce upgrades.
Company news also covers portfolio and infrastructure actions such as Masterflex fluid handling systems, single-use assemblies, peristaltic pumps, J.T. Baker high-purity process chemicals, and expanded microbial and stability testing capabilities for regulated biopharma manufacturing. Governance and management updates include finance leadership changes and appointments tied to bioscience, medtech products and enterprise transformation.
Avantor, Inc. (NYSE: AVTR) announced an underwritten secondary offering of 71,339,001 shares of common stock by certain stockholders, including an affiliate of New Mountain Capital, LLC. The underwriters, Goldman Sachs & Co. LLC and J.P. Morgan, may also purchase an additional 7,133,898 shares within 30 days. Avantor will not receive any proceeds from this offering, which has been registered with the SEC.
Prospective investors can obtain the necessary prospectus from the underwriters. This press release does not constitute an offer or solicitation for the shares.
Avantor executives participated in the Cell & Gene Therapy Bioprocessing & Commercialization Conference, discussing essential topics like process efficiency and scalability within the biopharmaceutical sector.
Dr. Ger Brophy highlighted the need for operational efficiency and automation to enhance accessibility to cell and gene therapies. Claudia Berrón emphasized collaboration among industry leaders to navigate challenges posed by COVID-19, focusing on supply chain disruptions and clinical trial delays. Avantor aims to support the development of novel treatments by partnering with leading pharmaceutical companies.
Avantor announced the pricing of €650 million of 2.625% Senior First Lien Notes due November 2025, up from a previously announced €550 million. The offering closes on November 6, 2020. The Notes are guaranteed by Vail Holdco Sub LLC and its subsidiaries, secured by tangible and intangible assets. Proceeds will redeem existing 6.000% and 4.750% Senior First Lien Notes due 2024. The offering is made under exemptions of the Securities Act, available only to qualified institutional buyers.
Avantor, a global provider of critical products and services in life sciences, announced the initiation of a private offering of euro-denominated senior first lien notes. These notes will be issued by its subsidiary, Avantor Funding, Inc., and guaranteed by its parent company and subsidiaries. The proceeds will be utilized to redeem existing senior notes due in 2024 and cover related expenses. The offering relies on exemptions from registration under the Securities Act, aimed at qualified institutional buyers. Avantor emphasizes its significant role within multiple industries and its extensive global reach.
Avantor, Inc. (AVTR) reported third-quarter 2020 net sales of $1.605 billion, up 6.7% year-over-year, with organic growth of 5.4%. However, the company faced a net loss of $42.2 million due to a $226.4 million debt extinguishment. Adjusted EBITDA increased 14% to $285.6 million, with a margin expansion of 112 basis points. Year-to-date cash flow from operations reached $623.8 million, a 134% rise. The conference call is scheduled for October 28, 2020, to discuss these results further.
Avantor, Inc. (NYSE: AVTR) reported preliminary unaudited revenues for Q3 2020, with total revenues of $1.60 billion, reflecting a 6.7% increase and 5.4% organic growth. The results indicate strong performance, particularly in the biopharma and healthcare markets. The company will release full financial results on October 28, 2020. It is important to note that these figures are preliminary and unaudited, pending final review.
Avantor, a leading global provider in life sciences and advanced technologies, has announced a quarterly cash dividend of $0.78 per share for its 6.250% Series A Mandatory Convertible Preferred Stock. This equates to a yield of 1.560% and will be payable on November 15, 2020, to shareholders recorded by November 1, 2020. This decision reflects Avantor's commitment to providing returns to its stakeholders while maintaining a strong position within the industry.
Avantor (NYSE: AVTR) announced that its General Counsel, Justin Miller, has been honored as a 'Legend In Law' by The Burton Awards Program, recognizing his outstanding legal achievements. He is one of 13 honorees this year, acknowledged for his exceptional reputation and contributions to the legal profession. Miller's career highlights include a significant federal case win at age 26 and leading Avantor's initial public offering in May 2019. The awards celebrate leaders who tackle complex legal challenges on a national and global scale.
Avantor, a global provider of mission-critical products and services, is set to release its third quarter 2020 financial results on October 28, 2020, after market close. A conference call will take place at 5:00 p.m. EDT the same day to discuss the results. Investors can join the call by dialing (866) 211-4132 domestically or (647) 689-6615 internationally, using access code 3557106. The earnings press release and related slides will be available on their website. A replay will be accessible until November 12, 2020.
Avantor has appointed Frederic Vanderhaegen as Executive Vice President for the Americas and Europe, effective immediately. He expands his role to include the Americas, enhancing the company's focus on customer research and development. This strategic move aims to improve customer service and innovation in the company’s offerings. Vanderhaegen, who joined Avantor in 2018, brings extensive leadership experience in the life sciences sector.